The Winship Cancer Institute Emory University
Welcome,         Profile    Billing    Logout  
 8 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kudchadkar, Ragini
NCT02964559: Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

Completed
2
11
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Emory University, Merck Sharp & Dohme LLC, National Institutes of Health (NIH), National Cancer Institute (NCI)
Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma
05/21
05/21
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
Gleason, Shannon
EXCEED ET, NCT05482971: A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Active, not recruiting
2
91
Canada, US
Ropeginterferon alfa-2b-njft (P1101), P1101
PharmaEssentia
Essential Thrombocythemia
03/27
03/27
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Jan 2024 - Dec 2024: Market entry for acute leukemias
Hourglass Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia
Dec 2022 - Dec 2023: Submission in US for relapsed/refractory acute leukemia
Jul 2023 - Sep 2023: Data from AUGMENT-101 trial for r/r AML
Checkmark Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
More
Recruiting
1/2
413
Europe, Canada, US, RoW
revumenib, SNDX-5613, cobicistat
Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
12/27
12/27
HQP1351CU101, NCT04260022: Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Recruiting
1
62
US
Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab, Blincyto
Ascentage Pharma Group Inc.
Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia
01/24
01/24
NCT04764474: A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

Recruiting
1
75
Europe, US
HMPL-306
Hutchmed
Isocitrate Dehydrogenase Gene Mutation
09/24
06/25
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Active, not recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
SX682-MDS-102, NCT04245397: Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome

Recruiting
1
151
US
SX-682, Decitabine, DEC-C
Syntrix Biosystems, Inc., H. Lee Moffitt Cancer Center and Research Institute, National Heart, Lung, and Blood Institute (NHLBI), AdventHealth, Emory University, University of Miami, Mayo Clinic, Montefiore Medical Center, National Cancer Institute (NCI), Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Myelodysplastic Syndromes
03/28
03/29
Prutch, Zachary
NCT05481151: A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Hourglass Feb 2024 - Dec 2024 : Topline data for adults with PV
Active, not recruiting
3
111
Canada, US
P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101)
PharmaEssentia
Polycythemia Vera
12/24
07/25
EXCEED ET, NCT05482971: A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Active, not recruiting
2
91
Canada, US
Ropeginterferon alfa-2b-njft (P1101), P1101
PharmaEssentia
Essential Thrombocythemia
03/27
03/27

Download Options